LCD Reference Article Response To Comments Article

Response to Comments: MolDX: Envisia, Veracyte, Idiopathic Pulmonary Fibrosis Diagnostic Test

A56366

Expand All | Collapse All

Contractor Information

Contractor Name	Contract Type	Contract Number	Jurisdiction	States
CGS Administrators, LLC	MAC - Part A	15101 - MAC A	J - 15	Kentucky
CGS Administrators, LLC	MAC - Part B	15102 - MAC B	J - 15	Kentucky
CGS Administrators, LLC	MAC - Part A	15201 - MAC A	J - 15	Ohio
CGS Administrators, LLC	MAC - Part B	15202 - MAC B	J - 15	Ohio

Article Information

General Information

Article ID
A56366

Article Title
Response to Comments: MolDX: Envisia, Veracyte, Idiopathic Pulmonary Fibrosis Diagnostic Test

Article Type
Response to Comments

Original Effective Date
04/04/2019

Retirement Date
N/A

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Copyright © 2024, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution, or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312‐893‐6816.

Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.

Article Guidance

Article Text

The comment period for the Response to Comments: MolDX: Envisia, Veracyte, Idiopathic Pulmonary Fibrosis Diagnostic Test DL37905 began on 11/15/2018 and
ended on 12/29/2018. Comments were received from the provider community. The notice period begins on 04/04/2019 and ends 05/19/2019. The LCD becomes final on 05/20/2019.

Response To Comments

Number	Comment	Response
1	I am the Director of the Advanced Lung Disease Program and Medical Director of the lung transplant program at Inova Fairfax Hospital in Falls Church, Virginia. I regularly diagnose patients with interstitial lung disease and manage these patients with various therapies, including antifibrotics in those with IPF. I have served on multiple committees, including FDA advisory boards and steering committees for clinical trials in IPF. I am a paid consultant to Veracyte and am also involved in their clinical trial, BRAVE, that was used to train and validate the Envisia classifier. I want to express my support for your determination that Envisia is medically necessary and reasonable for Medicare patients with a HRCT of the chest demonstrating a probable UIP pattern and/or Indeterminate for UIP. My first recommendation is to simplify your criteria for "Situations in which Envisia should not be used." I recommend you delete the second sentence in bullet number two; "In particular, Envisia should not be used if any of the following findings are present on HRCT," and delete the list of radiographic features that follow. In my clinical experience, there is rarely one single HRCT feature that results in us categorically defining a patient as being "consistent with a nonlPF diagnosis." It is the collective evaluation of a patient's demographics, clinical history, environmental exposures, and the HRCT features that lead to an overall assessment. Additionally, several of the features listed as exclusion criteria for Envisia use can be present, in some form or degree, in patients with an indeterminate UIP or probable UIP pattern. Agreement can be limited as to the extent and importance of these exact features on HRCT among radiologists as well as ILD clinicians. A second recommendation would be to allow the use of the Envisia test in select patients who have "CT features most consistent with non-IPF diagnosis". IPF is a disease of the elderly and the older the patient, the greater the likelihood that any ILD is IPF, especially if other causes have methodically been ruled out through a thorough history, physical examination and connective tissue disease panel. Indeed, there is data to suggest that up to 50% of elderly patients (for example>70 years) who have such a HRCT pattern might still have UIP once subjected to lung biopsy. In such a scenario where the pretest likelihood of IPF is very high but the CT is inconsistent, the Envisia test might have a role since these patients might warrant bronchoscopy anyway to elucidate the cause of their ILO. If the Envisia is positive in these circumstances, it might be sufficient to tip the diagnosis to IPF and thereby forego the need for a surgical lung biopsy. In conclusion, I support finalizing your coverage determination for the Envisia test, and simplifying the situations in which Envisia should not be used to the categorical diagnosis of a typical UIP pattern on HRCT only.	Please see below for response.
2	I am writing to provide comments on Proposed Local Coverage Determination (LCD): MolDX: ENVISIA, Veracyte, Idiopathic Pulmonary Fibrosis Diagnostic Test (DL37919). I am a pulmonotogist in practice at Columbia University Irving Medical Center in New York City where I am co-director of the interstitial lung disease program. I have considerable expertise in the clinical care of adults with idiopathic pulmonary fibrosis. By way of disclosure, I have received consulting fees from Veracyte in the past, and I continue to have a consulting arrangement with Veracyte for which I receive no fees. I will also disclose that I provided guidance by telephone to Jim Almas during the development of the draft LCD. I have the following comments: I believe that the listing of specific CT findings is too restrictive. Clinicians should be left to decide if a CT scan does or does not meet Fleischner CT criteria. In particular, I suggest removing the following text: "Envisia should not be used if any of the following findings are present on HRCT: more than mild ground-glass opacities present in areas away from reticulation more than mild mosaic ground-glass attenuation more than mild expiratory gas trapping pattern peribronchovascular-predominant distribution of disease (as compared to a subpleural- predominant distribution) Substantial upper lobe predominance Unilateral or focal findings Subpleural sparing Diffuse nodules Diffuse cysts" I believe the following statement is ill-informed and misleading: "Patients with an HRCT suggestive of definitive UIP for whom the clinician would recommend testing in lieu of surgical lung biopsy to definitively confirm histopathologic UIP." This sentence cannot be applied in clinical practice. I strongly suggest deleting this sentence or changing the work "testing" to "IPF treatment.”	Please see below for response.
3	As the Chief Scientific and Medical Officer at Veracyte, Inc, South San Francisco, CA, it is my pleasure to provide you with the enclosed comments regarding the Proposed Local Coverage Determination (LCD): Envisia, Veracyte, Idiopathic Pulmonary Fibrosis Diagnostic Test (DL37857). I support Palmetto's proposal to provide coverage for Medicare beneficiaries for the Envisia Genomic Classifier testing for patients with interstitial lung disease whom are suspected of idiopathic pulmonary fibrosis. My enclosed comments are intended to specifically: Express my support for the MolDx Program and finalizing the Envisia Draft LCD Provide recommendations regarding the Criteria for Coverage I would like to thank you and the Palmetto MolDx team for your thoughtful review of the literature regarding interstitial lung diseases and Envisia Genomic Classifier testing. I believe the Envisia classifier will improve the safety and efficacy of the diagnosis of interstitial lung disease and idiopathic pulmonary fibrosis for Medicare beneficiaries.	Please see below for response.
4	I practice at the University of Chicago where I am an Associate Professor of Radiology, Section Chief of Thoracic Radiology, and the Interim Vice Chair for Quality in the Department of Radiology. In my practice, I specialize in cardiopulmonary imaging, and have expertise in the interpretation of chest CT of patients presenting with interstitial lung diseases. I am published researcher with interests in the imaging features that present when patients harbor an interstitial lung disease. I want to complement you on your accurate and complete review of the diagnosis and management of patients presenting with interstitial lung disease with idiopathic pulmonary fibrosis in the differential diagnosis. The imaging and pathologic diagnosis of this disease is complex and highly variable from clinician to clinician, leading to suboptimal patient outcomes. The addition of diagnostic tools such as Envisia should help to improve standardization of the diagnosis and treatment of patients suspected of IPF. I support your decision that the Envisia Genomic Classifier is medically reasonable and appropriate for Medicare beneficiaries presenting with “Probable UIP” and “Indeterminate for UIP” as described in the 2018 Fleischner Society White Paper on the Diagnostic Criteria for Idiopathic Pulmonary Fibrosis. These are the cases that challenge clinicians, including myself, the greatest in clinical practice, and where a genomic classifier will most significantly improve patient outcomes. Based on my own published research, I strongly recommend that you revise the section titled “Situations in which Envisia should not be used” within the Criteria for Coverage. It is appropriate to suggest under the first bullet that Envisia should not be used when a “Typical UIP” pattern on HRCT is observed as defined by the 2018 Fleischner Society whitepaper. However, I recommend you revise the second bullet by deleting the statement I have struck through below: “CT features most consistent with non-IPF diagnosis” on HRCT as defined by the 2018 Fleichner Society White paper. In particular, Envisia should not be used if any of the following findings are present on HRCT: More than mild ground-glass opacities present in the areas away from reticulation More than mild mosaic ground-glass attenuation More than mild expiratory gas trapping pattern Peribronchovascular-predominant distribution of disease (as compared to subpleural-predominant distribution) Substantial upper lobe predominance Unilateral or focal findings Subpleural sparing Diffuse nodules Diffuse cysts The 2018 Fleichner Society White paper identifies these features as being “most consistent with a non-IPF diagnosis.” The authors did not intend to imply that these features NEVER appear in the presence of UIP and a clinical IPF diagnosis. I was the lead author of one of the most significant studies evaluating HRCT and histologic features present in patients by UIP diagnostic category in the journal CHEST2. In Table 3 from that study (attached), several of the features listed as criteria to exclude the use of Envisia were present in patients with “Probable UIP” and “Indeterminate for UIP.” For example, while substantially more ground-glass opacities were present in the Inconsistent with UIP group (95%), ground-glass opacities were found in 23% of patients Indeterminate for UIP, and in 7% of patients with Probable UIP. I believe the 2018 Fleischner Society White Paper provides an excellent framework for clinicians to make a categorical assign a likelihood of UIP from which the criteria for Envisia coverage can be derived. As you point out in the background of your literature review, the coexistence of multiple radiographic features is what makes this diagnosis so challenging. Explicitly excluding patients from Envisia testing due to the presence of a single HRCT feature may result in patients not receiving the optimal treatment. In summary, I am supportive of your draft Local Coverage Determination for the Envisia Genomic Classifier. And I recommend you limit the “Situations in which Envisia should not be used” to the clinician’s categorical determination of “Typical UIP” or “CT Features most consistent with a non-IPF diagnosis,” and not explicitly exclude coverage in the presence or absence of any single HRCT feature. I appreciate your consideration of my comments.	Thank you all for your comments. Because all comments are in regards to the same principle topics, they are all addressed concurrently here. We hope this policy will help Medicare beneficiaries have access to necessary and reasonable testing that may prevent unnecessary invasive procedures. In regards to the comments regarding restricting use of Envisia to prohibit its use with radiological evidence that is not consistent with a diagnosis of IPF, we agree that the language used in the draft LCD may be too restrictive and not result in the intended utilization of the test. We have now revised the LCD to clarify that individual radiological findings do not individually preclude the coverage of the test, but maintain that testing should be restricted to suspected IPF. We therefore preclude coverage when HRCT suggests a “non-IPF diagnosis” or a “Typical UIP” pattern. Regarding the use of Envisia for patients who have HRCT findings consistent with “non-IPF diagnosis,” the data would have to clearly show benefit for the use of this test in the Medicare patient population to expand coverage to this category. Lastly, as identified in one comment, unclear language suggesting testing and histologic confirmation in lieu of this test with definitive IPF HRCT has been removed from the coverage policy.

Coding Information

Bill Type Codes

Code	Description
Please accept the License to see the codes.

Revenue Codes

Code	Description
Please accept the License to see the codes.

CPT/HCPCS Codes

Expand All | Collapse All

Please accept the License to see the codes.

ICD-10-CM Codes that Support Medical Necessity

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

ICD-10-CM Codes that DO NOT Support Medical Necessity

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

ICD-10-PCS Codes

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

Additional ICD-10 Information

Bill Type Codes

Code	Description
Please accept the License to see the codes.

Revenue Codes

Code	Description
Please accept the License to see the codes.

Coding Table Information

Excluded CPT/HCPCS Codes - Table Format

Code	Descriptor Generic Name	Descriptor Brand Name	Exclusion Effective Date	Exclusion End Date	Reason for Exclusion
			N/A	N/A

Non-Excluded CPT/HCPCS Ended Codes - Table Format

Code	Descriptor Generic Name	Descriptor Brand Name	Exclusion Effective Date	Exclusion End Date	Reason for Exclusion

Revision History Information

N/A

Associated Documents

Related Local Coverage Documents
LCDs
L37905 - MolDX: Envisia™, Veracyte™, Idiopathic Pulmonary Fibrosis Diagnostic Test

Updated On	Effective Dates	Status
03/29/2019	04/04/2019 - N/A	Currently in Effect	You are here

Keywords

N/A

Read the Article Disclaimer

License Agreements
American Medical Association Current Procedural Terminology
American Dental Association Current Dental Terminology
American Hospital Association NUBC UB-04

Please review the licensing information below and indicate your agreement and acceptance.

License for Use of Current Procedural Terminology (CPT)

End User Point and Click Agreement: CPT codes, descriptions and other data only are copyright 2023 American Medical Association. All Rights Reserved (or such other date of publication of CPT). CPT is a trademark of the American Medical Association (AMA).

You, your employees, and agents are authorized to use CPT only as agreed upon with the AMA internally within your organization within the United States for the sole use by yourself, employees, and agents. Use is limited to use in Medicare, Medicaid or other programs administered by the Centers for Medicare and Medicaid Services (CMS). You agree to take all necessary steps to insure that your employees and agents abide by the terms of this agreement.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CPT for resale and/or license, transferring copies of CPT to any party not bound by this agreement, creating any modified or derivative work of CPT, or making any commercial use of CPT. License to use CPT for any use not authorized herein must be obtained through the AMA, CPT Intellectual Property Services, AMA Plaza, 330 Wabash Ave., Suite 39300, Chicago, IL 60611-5885. Applications are available at the AMA Web site, http://www.ama-assn.org/go/cpt http://www.ama-assn.org/go/cpt.

Applicable FARS\DFARS Restrictions Apply to Government Use.

This product includes CPT which is commercial technical data and/or computer data bases and/or commercial computer software and/or commercial computer software documentation, as applicable which were developed exclusively at private expense by the American Medical Association, AMA Plaza, 330 N. Wabash Ave., Suite 39300, Chicago, IL 60611-5885. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of FAR 52.227-14 (December 2007) and/or subject to the restricted rights provisions of FAR 52.227-14 (December 2007) and FAR 52.227-19 (December 2007), as applicable, and any applicable agency FAR Supplements, for non-Department of Defense Federal procurements.

The scope of this license is determined by the AMA, the copyright holder. Any questions pertaining to the license or use of the CPT should be addressed to the AMA. End Users do not act for or on behalf of the CMS. CMS disclaims responsibility for any liability attributable to end user use of the CPT. CMS will not be liable for any claims attributable to any errors, omissions, or other inaccuracies in the information or material contained on this page. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

License For Use of Current Dental Terminology (CDT^TM)

The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. By clicking below on the button labeled "I accept", you hereby acknowledge that you have read, understood, and agreed to all terms and conditions set forth in this agreement.

If you do not agree with all terms and conditions set forth herein, click below on the button labeled "I do not accept" and exit from this computer screen.

If you are acting on behalf of an organization, you represent that you are authorized to act on behalf of such organization and that your acceptance of the terms of this agreement creates a legally enforceable obligation of the organization. As used herein, "you" and "your" refer to you and any organization on behalf of which you are acting.

Subject to the terms and conditions contained in this Agreement, you, your employees and agents are authorized to use CDT only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of CDT is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this agreement. You acknowledge that the ADA holds all copyright, trademark and other rights in CDT. You shall not remove, alter, or obscure any ADA copyright notices or other proprietary rights notices included in the materials.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CDT for resale and/or license, transferring copies of CDT to any party not bound by this agreement, creating any modified or derivative work of CDT, or making any commercial use of CDT. License to use CDT for any use not authorized herein must be obtained through the American Dental Association, 211 East Chicago Avenue, Chicago, IL 60611. Applications are available at the American Dental Association web site, http://www.ADA.org/ http://www.ADA.org/.

Applicable Federal Acquisition Regulation Clauses (FARS)/Department of Defense Federal Acquisition Regulation supplement (DFARS) Restrictions Apply to Government Use.

Organizations who contract with CMS acknowledge that they may have a commercial CDT license with the ADA, and that use of CDT codes as permitted herein for the administration of CMS programs does not extend to any other programs or services the organization may administer and royalties dues for the use of the CDT codes are governed by their commercial license.

ADA DISCLAIMER OF WARRANTIES AND LIABILITIES

CDT is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. No fee schedules, basic unit, relative values, or related listings are included in CDT. The ADA does not directly or indirectly practice medicine or dispense dental services. The sole responsibility for software, including any CDT and other content contained therein, is with (insert name of applicable entity) or the CMS; and no endorsement by the ADA is intended or implied. The ADA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement. The ADA is a third-party beneficiary to this Agreement.

CMS DISCLAIMER

The scope of this license is determined by the ADA, the copyright holder. Any questions pertaining to the license or use of the CDT should be addressed to the ADA. End Users do not act for or on behalf of the CMS. CMS disclaims responsibility for any liability attributable to end user use of the CDT. CMS will not be liable for any claims attributable to any errors, omissions, or other inaccuracies in the information or material covered by this license. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. If the foregoing terms and conditions are acceptable to you, please indicate your agreement by clicking below on the button labeled "I Accept". If you do not agree to the terms and conditions, you may not access or use software. Instead, you must click below on the button labeled "I Do Not Accept" and exit from this computer screen.

License For Use of National Uniform Billing Committee (NUBC) UB-04

These materials contain NUBC Official UB-04 Specifications (UB-04 Data), which is copyrighted by the American Hospital Association (AHA).

THE LICENSE GRANTED HEREIN IS EXPRESSLY CONDITIONED UPON YOUR ACCEPTANCE OF ALL TERMS AND CONDITIONS CONTAINED IN THIS AGREEMENT. BY CLICKING BELOW ON THE BUTTON LABELED "I ACCEPT", YOU HEREBY ACKNOWLEDGE THAT YOU HAVE READ, UNDERSTOOD AND AGREED TO ALL TERMS AND CONDITIONS SET FORTH IN THIS AGREEMENT.

IF YOU DO NOT AGREE WITH ALL TERMS AND CONDITIONS SET FORTH HEREIN, CLICK BELOW ON THE BUTTON LABELED "I DO NOT ACCEPT" AND EXIT FROM THIS COMPUTER SCREEN. IF YOU ARE ACTING ON BEHALF OF AN ORGANIZATION, YOU REPRESENT THAT YOU ARE AUTHORIZED TO ACT ON BEHALF OF SUCH ORGANIZATION AND THAT YOUR ACCEPTANCE OF THE TERMS OF THIS AGREEMENT CREATES A LEGALLY ENFORCEABLE OBLIGATION OF THE ORGANIZATION. AS USED HEREIN, "YOU" AND "YOUR" REFER TO YOU AND ANY ORGANIZATION ON BEHALF OF WHICH YOU ARE ACTING.

Subject to the terms and conditions contained in this Agreement, you, your employees, and agents are authorized to use UB-04 Data only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of UB-04 Data is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this Agreement. You acknowledge that the AHA holds all copyright, trademark, and other rights in UB-04 Data. You shall not remove, alter, or obscure any AHA copyright notices or other proprietary rights notices included in the materials.
Any use not authorized herein is prohibited, including, by way of illustration and not by way of limitation, making copies of UB-04 Data for resale and/or license, transferring copies of UB-04 Data to any party not bound by this agreement, creating any modified or derivative work of UB-04 Data, or making any commercial use of UB-04 Data. License to use UB-04 Data for any use not authorized herein must be obtained through the American Hospital Association, 155 N. Wacker Drive, Suite 400, Chicago, Illinois, 60606. Applications are available at the NUBC website, http://www.nubc.org/ http://www.nubc.org/.
The UB-04 Data included in this product is commercial technical data and/or computer databases and/or commercial computer software and/or commercial computer software documentation, as applicable, which was developed exclusively at private expense by the American Hospital Association, 155 N. Wacker Drive, Suite 400, Chicago, Illinois 60606. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of DFARS 252.227-7015(b)(2) (November 1995) and/or subject to the restrictions of DFARS 227.7202-1(a) (June 1995) and DFARS 227.7202-3(a) (June 1995), as applicable for U.S. Department of Defense procurements and the limited rights restrictions of FAR 52.227-14 (December 2007) and FAR 52.227-19 (December 2007), as applicable, and any applicable agency FAR Supplements, for non-Department of Defense Federal procurements.
AHA DISCLAIMER OF WARRANTIES AND LIABILITIES. UB-04 Data is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. The sole responsibility for the software, including any UB-04 Data and other content contained therein, is with the Medicare/Medicaid Contractor or the CMS; and no endorsement by the AHA is intended or implied. The AHA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement. The AHA is a third-party beneficiary to this Agreement.
CMS DISCLAIMER. The scope of this license is determined by the AHA, the copyright holder. Any questions pertaining to the license or use of the UB-04 Data should be addressed to the AHA. End users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE UB-04 DATA. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL COVERED BY THIS LICENSE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

Submit Feedback/Ask a Question

Response to Comments: MolDX: Envisia, Veracyte, Idiopathic Pulmonary Fibrosis Diagnostic Test

Document Note

Note History

Contractor Information

Article Information

General Information

CMS National Coverage Policy

Article Guidance

Response To Comments

Coding Information

Bill Type Codes

Please accept the License to see the codes.

Revenue Codes

Please accept the License to see the codes.

CPT/HCPCS Codes

Please accept the License to see the codes.

CPT/HCPCS Modifiers

Group 1

ICD-10-CM Codes that Support Medical Necessity

Group 1

ICD-10-CM Codes that DO NOT Support Medical Necessity

Group 1

ICD-10-PCS Codes

Group 1

Additional ICD-10 Information

Bill Type Codes

Please accept the License to see the codes.

Revenue Codes

Please accept the License to see the codes.

Other Coding Information

Group 1

Coding Table Information

Revision History Information

Associated Documents

Keywords

Page Help for Article - Response to Comments: MolDX: Envisia, Veracyte, Idiopathic Pulmonary Fibrosis Diagnostic Test (A56366)

Introduction

Finding a specific code

More information

Printing a Document to PDF

Get email updates

CMS & HHS WEBSITES

HELPFUL LINKS

RSS FEEDS